Missionirnewsbreaks Nutriband Inc. (NASDAQ: NTRB) Eyes Clear Development Pathway For AVERSA(TM) Technology

(MENAFN- Investor Brand Network) Nutriband (NASDAQ: NTRB) is a transdermal pharmaceutical developer that has secured crucial FDA engagement for its lead abuse-deterrent technology.“Nutriband's FDA Type C Meeting approval for AVERSA(TM) Fentanyl signals agency recognition of the product's potential to address critical unmet medical needs. The Sept. 18 meeting with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine focuses on Chemistry, Manufacturing, and Controls ('CMC') plans spanning the entire development and commercialization timeline,” reads a recent article.“This milestone addresses the complete development arc from IND submission through 505(b)(2) NDA approval. The 505(b)(2) pathway allows Nutriband to leverage existing fentanyl safety data while focusing regulatory review on novel abuse-deterrent components.”

To view the full article, visit

About Nutriband Inc.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information about the company, visit .

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company's newsroom at

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: imer, Texas

512.354.7000 Office
href="/cdn-cgi/l/email-protection#70351419041f02303d190303191f1e39225e131f1d" target="_blank" rel="noreferrer noopener">[email protected]

MissionIR is powered by IBN

MENAFN19092025000224011066ID1110085604